Update shared on07 Aug 2025
Fair value Increased 14%Despite a marked slowdown in consensus revenue growth forecasts, a significant improvement in net profit margin has driven the consensus analyst price target for Rigel Pharmaceuticals up from $33.74 to $36.83.
What's in the News
- Raised 2025 total revenue guidance to $270–280 million (from $200–210 million), with net product sales of $210–220 million and collaboration contract revenues of $60 million (from $15–18 million).
- Anticipates reporting positive net income for 2025 while funding clinical development programs.
- Dropped from numerous value and small/microcap indices, including various Russell benchmarks (3000 Value, Small Cap Comp Value, 3000E Value, 2000 Value, Microcap Value, 2500 Value).
Valuation Changes
Summary of Valuation Changes for Rigel Pharmaceuticals
- The Consensus Analyst Price Target has risen from $33.74 to $36.83.
- The Consensus Revenue Growth forecasts for Rigel Pharmaceuticals has significantly fallen from 9.2% per annum to 3.5% per annum.
- The Net Profit Margin for Rigel Pharmaceuticals has significantly risen from 14.08% to 18.54%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.